title: ProteinChip technology is a useful method in the pathogenesis and diagnosis of endometriosis: a preliminary study.
abstract: OBJECTIVE
  To test the feasibility of ProteinChip (Ciphergen Biosystems, Inc., Fremont, CA) technology as a proteomic tool in discovering and identifying proteins that are differentially expressed in endometrium, endometriotic tissue, and normal peritoneum from women with and without endometriosis.
  
  
  METHODS
  Differential analysis of protein expression in women with and without endometriosis.
  
  
  METHODS
  University hospital.
  
  
  METHODS
  A total of nine patients during their secretory phase (days 20-22) were selected for this study on the basis of cycle phase and presence/or absence of endometriosis.
  
  
  METHODS
  Twelve tissues used in the study included six endometrial biopsies from women with mild endometriosis (n = 3) and a normal pelvis (n = 3) as well as paired samples of peritoneal endometriotic lesions (n = 3) and macroscopically normal peritoneum biopsies (n = 3) from three women with endometriosis.
  
  
  METHODS
  Numerous expression differences were observed in the above comparisons, representing both up-regulation and down-regulation in protein and peptide expression levels.
  
  
  RESULTS
  Endometrial expression for a number of proteins and peptides in the range of 2.8-12.3 kDa was 3-24 times lower in women with endometriosis than in those without endometriosis. When compared with normal peritoneum, endometriotic lesions showed an increased expression for a set of proteins and peptides in the range of 3-96 kDa, and especially an up-regulated cluster of proteins between 22 and 23 kDa, identified to be transgelin, a smooth muscle actin-binding protein.
  
  
  CONCLUSIONS
  This preliminary study demonstrated that differential protein profiling by using ProteinChip array technology is feasible, reproducible, and may be developed into a powerful tool for endometriosis research.
authors.affiliation: Leuven University Fertility Centre, Department of Obstetrics and Gynaecology, Leuven, Belgium.
authors.forename: Cleophas M
authors.initials: CM
authors.lastname: Kyama
authors.forename: Davy
authors.initials: D
authors.lastname: T'Jampens
authors.forename: Attila
authors.initials: A
authors.lastname: Mihalyi
authors.forename: Peter
authors.initials: P
authors.lastname: Simsa
authors.forename: Sophie
authors.initials: S
authors.lastname: Debrock
authors.forename: Etienne
authors.initials: E
authors.lastname: Waelkens
authors.forename: Bart
authors.initials: B
authors.lastname: Landuyt
authors.forename: Christel
authors.initials: C
authors.lastname: Meuleman
authors.forename: Vilmos
authors.initials: V
authors.lastname: Fulop
authors.forename: Jason M
authors.initials: JM
authors.lastname: Mwenda
authors.forename: Thomas M
authors.initials: TM
authors.lastname: D'Hooghe
mesh_terms: D015415:Biomarkers / Q000032:analysis; D002478:Cells, Cultured; D004715:Endometriosis / Q000175:diagnosis* / Q000378:metabolism*; D005260:Female; D020869:Gene Expression Profiling / Q000379:methods*; D006801:Humans; D010865:Pilot Projects; D040081:Protein Array Analysis / Q000379:methods*; D011506:Proteins / Q000032:analysis*; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity
chemical_list: D015415:Biomarkers; D011506:Proteins